The safety of available treatments options for neuroendocrine tumors
| Autor: | A. Colao, Roberta Modica, Antongiulio Faggiano, Genoveffa Pizza, F. Lo Calzo |
|---|---|
| Přispěvatelé: | Faggiano, A., Lo Calzo, F., Pizza, G., Modica, R., Colao, A. |
| Rok vydání: | 2017 |
| Předmět: |
Radioisotope
safety 0301 basic medicine Oncology medicine.medical_specialty Receptors Peptide Peptide receptor drug design molecular targeted therapy medicine.medical_treatment somatostatin analogue receptors somatostatin Pharmacology Neuroendocrine tumors Targeted therapy Antineoplastic Agent Chemotherapy neuroendocrine neoplasm PRRT somatostatin analogues targeted therapy animals antineoplastic agents humans neuroendocrine tumors radioisotopes peptide pharmacology (medical) 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Pharmacology (medical) Adverse effect Animal business.industry General Medicine medicine.disease Discontinuation 030104 developmental biology 030220 oncology & carcinogenesis Radionuclide therapy Dose reduction Neuroendocrine Tumor business Human |
| Zdroj: | Expert Opinion on Drug Safety. 16:1149-1161 |
| ISSN: | 1744-764X 1474-0338 |
| Popis: | Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to summarize the current knowledge upon safety of all systemic treatment options available. Thirty three different clinical studies have been considered, including 4 on somatostatin analogues (SSA), 5 on targeted therapies, 10 on peptide receptor radionuclide therapy (PRRT), and 14 on chemotherapy. Expert opinion: SSA are safe and well tolerated without any relevant severe adverse event and very low treatment discontinuation rate. Targeted therapies show a satisfying safety profile. Most adverse events are grade 1-2 and easy manageable with dose reduction or temporary interruption. PRRT is manageable and safe with a low rate of grade 3-4 adverse events. However, severe renal and hematologic toxicity may occur. Chemotherapy is usually considered after previous therapeutic lines. Therefore, these subjects are more susceptible to experience adverse events due to cumulative toxicities or poor performance status. The available systemic treatment options are generally well tolerated and suitable for long-term administration. Cumulative toxicity should be taken in account for the definition of therapeutic sequence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|